MSOS, the AdvisorShares Pure US Cannabis ETF, is trading at its highest levels of 2026, and the timing is not incidental. A DEA administrative hearing set for June 29 will examine whether marijuana products broadly, not just state-licensed medical formulations, should move to Schedule III, and traders are positioning ahead of that outcome. Trulieve's arrival on the New York Stock Exchange this week has become the headline event pulling capital into the sector, but the bigger story is what a favorable Schedule III ruling would mean for balance sheets across the multi-state operator landscape.
As of May 31, MSOS posted a 103.7% one-year net asset value return, dwarfing the North American Marijuana Index's 36.9% gain and well ahead of the S&P 500's 29.8%. Over the trailing three months, MSOS climbed 28% while the broader marijuana benchmark actually slipped about 1%, a divergence that tells you money is chasing specific catalysts, not the sector as a whole. For operators trying to make sense of valuation swings this sharp, the operational back office still matters just as much as market sentiment; retailers running compliant, auditable inventory through platforms like cannabis dispensary management software california continue to be the ones best positioned to prove out margin claims to skeptical institutional buyers once capital markets open up further. cannabis dispensary management software california
Why Trulieve's Listing Is More Than a Ticker Change
Trulieve, which makes up roughly 30% of MSOS assets, began trading on the NYSE under TRLV this week after restructuring to separate its medical cannabis operations from its adult-use business. That separation wasn't cosmetic - it was the mechanism that allowed the company to clear listing standards on a senior U.S. exchange, something no plant-touching, U.S.-based multi-state operator has managed before. CEO Kim Rivers linked the milestone directly to the federal move reclassifying medical marijuana to Schedule III, and Alliance Global has pointed to Trulieve's concentration in medical-only states, plus its exposure to expanding markets like Texas and Georgia, as a structural advantage heading into further reform.
Here's the catch, though: a listing is not the same as full legalization or interstate commerce. Trulieve, and any operator that follows it onto a senior exchange, still operates under a patchwork of state licensing regimes, seed-to-sale tracking mandates, and 280E tax exposure that a Schedule III reclassification would only partially unwind. The tax relief matters enormously - deducting ordinary expenses like payroll, rent, and interest changes the math for thin-margin retailers - but it doesn't erase state-by-state compliance burdens around packaging, lab testing, or advertising restrictions that dispensary operators live with daily.
What the Rescheduling Hearing Actually Decides
The June 29 hearing, expected to run through no later than July 15, will determine whether adult-use cannabis products get folded into the same Schedule III framework already extended to state-licensed medical marijuana under Acting Attorney General Todd Blanche's April action. Trump's formal nomination of Blanche to serve as permanent attorney general has added to bullish sentiment, since it signals continuity on cannabis policy rather than a reversal. AdvisorShares has said the shift could strengthen earnings, free cash flow, and balance sheets across the industry while opening doors to banking services and institutional capital that plant-touching operators have long been shut out of.
Roth Capital called the rescheduling order "extremely favorable," citing benefits for taxation, capital access, and future uplistings. That's already showing up in financing activity: Cresco Labs secured a $50 million revolving credit facility from Needham Bank this week, which CEO Charlie Bachtell described as a non-dilutive tool for acquisitions and a step toward a senior exchange listing. Tilray, though not an MSOS holding, has also signaled it may deploy proceeds from a recent at-the-market program toward acquisitions tied to reform expectations.
Where the Upside Concentrates - and Where Caution Belongs
Trulieve may be the poster child, but it's not the ETF's biggest upside story. Verano carries the highest analyst upside among MSOS holdings at roughly 195%, followed by Jushi Holdings near 183% and Cresco Labs close to 99%, according to Koyfin data. Among the larger positions, Green Thumb Industries stands out with about 70% projected upside, ahead of both Trulieve and Curaleaf, the world's largest cannabis company by revenue. Glass House is the outlier with a projected downside near 22%, a reminder that rescheduling optimism isn't lifting every stock uniformly.
Retail sentiment on platforms like Stocktwits has turned "extremely bullish" on MSOS, Trulieve, and Green Thumb amid heavy message volume, with Tilray and Cresco drawing similar enthusiasm. That kind of retail energy is worth watching but not worth mistaking for certainty. A hearing outcome is not guaranteed to land the way markets are pricing it, and operators, landlords, and payment providers tied to cannabis retail should treat this rally as a signal to prepare for multiple regulatory scenarios, not a confirmation that federal reform is settled business.
